Focus on brain angiotensin III and aminopeptidase a in the control of hypertension

International Journal of Hypertension

Volumn 2012, Issue , 2012, Pages

  Wright, John W ^a   Mizutani, Shigehiko ^b   Harding, Joseph W ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Daiya Building Lady's Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; AMASTATIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN III; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BESTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; G PROTEIN COUPLED RECEPTOR; GLUTAMYL AMINOPEPTIDASE; LOSARTAN; MICROSOMAL AMINOPEPTIDASE; PLACEBO; PROTEIN INHIBITOR; RB 150; RENIN INHIBITOR; UNCLASSIFIED DRUG;

BLOOD PRESSURE REGULATION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPERTENSION; HYPOTENSION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 84868274694     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.1155/2012/124758     Document Type: Review

References (147)

1. Tigerstedt R., Bergman P. G., Niere und Kreislauf. Scandinavian Archives of Physiology 1898 8 223 271
2. Goldblatt H., Lynch J., Hanzal R. G., Summerville W. W., Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. The Journal of Experimental Medicine 1934 59 3 347 379
3. Braun-Menendez E., Fasciolo J. C., Leloir L. F., Munoz J. M., The substance causing renal hypertension. Journal of Physiology 1940 98 3 283 298
4. Page I. H., Helmer O. M., A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin activator. The Journal of Experimental Medicine 1940 71 1 29 42
5. Elliott D. F., Peart W. S., Amino-acid sequence in a hypertensin. Nature 1956 177 4507 527 528 2-s2.0-0000591551 10.1038/177527a0
6. Skeggs L. T., Lentz K. E., Kahn J. R., Shumway N. P., Woods K. R., The amino acid sequence of hypertensin. II. The Journal of Experimental Medicine 1956 104 2 193 197 2-s2.0-0001179034
7. Bumpus F. M., Schwarz H., Page I. H., Synthesis and pharmacology of the octapeptide angiotonin. Science 1957 125 3253 886 887 2-s2.0-12444316765
8. Johnston C. I., Biochemistry and pharmacology of the renin-angiotensin system. Drugs 1990 39 1 21 31 2-s2.0-0025101253 (Pubitemid 20050793)
9. Karamyan V. T., Speth R. C., Enzymatic pathways of the brain renin-angiotensin system: unsolved problems and continuing challenges. Regulatory Peptides 2007 143 13 15 27 2-s2.0-34547657601 10.1016/j.regpep.2007. 03.006 (Pubitemid 47212528)
10. Speth R. C., Karamyan V. T., The significance of brain aminopeptidases in the regulation of the actions of angiotensin peptides in the brain. Heart Failure Reviews 2008 13 3 299 309 2-s2.0-42049097442 10.1007/s10741-007-9078-2
11. Ferrario C. M., Strawn W. B., Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. American Journal of Cardiology 2006 98 1 121 128 2-s2.0-33745162185 10.1016/j.amjcard.2006.01. 059 (Pubitemid 43902687)
12. Kokubu T., Ueda E., Joh T., Nishimura K., Purification and properties of angiotensin I-converting enzyme in human lung and its role on the metabolism of vasoactive peptides in pulmonary circulation. Advances in Experimental Medicine and Biology 1979 120 467 475 2-s2.0-0018556554
13. Unger T., Li J., The role of the renin-angiotensin-aldosterone system in heart failure. JRAAS 2004 5 1, supplement S7 S10 2-s2.0-6444220362 (Pubitemid 39406441)
14. Rich D. H., Moon B. J., Harbeson S., Inhibition of aminopeptidases by amastatin and bestatin derivatives. Effect of inhibitor structure on slow-binding processes. Journal of Medicinal Chemistry 1984 27 4 417 422 2-s2.0-0021277915 (Pubitemid 14133727)
15. 2+-activated aspartate aminopeptidase activity, subcellular localization in young and adult rat brain. Brain Research 1990 522 1 165 167 2-s2.0-0025195260 10.1016/0006-8993(90)91595-8 (Pubitemid 20208803)
16. Wilk S., Healy D. P., Glutamyl aminopeptidase (aminopeptidase A), the BP-1/6C3 antigen. Advances in Neuroimmunology 1993 3 3 195 207 2-s2.0-0000358425
17. Chauvel E. N., Llorens-Cortes C., Coric P., Wilk S., Roques B. P., Fournie- Zaluski M. C., Differential inhibition of aminopeptidase A and aminopeptidase N by new β -amino thiols. Journal of Medicinal Chemistry 1994 37 18 2950 2957 2-s2.0-0027934524 (Pubitemid 24297812)
18. Unger T., Badoer E., Ganten D., Lang R. E., Rettig R., Brain angiotensin: pathways and pharmacology. Circulation 1988 77 6, part 2 I40 I54 2-s2.0-0023913168
19. Saavedra J. M., Brain and pituitary angiotensin. Endocrine Reviews 1992 13 2 329 380 2-s2.0-0026773791 10.1210/er.13.2.329
20. Speth R. C., Brown T. E., Barnes R. D., Wright J. W., Brain angiotensinergic activity: the state of our current knowledge. Proceedings of the Western Pharmacology Society 2003 46 11 15 2-s2.0-0344874562 (Pubitemid 37463421)
21. Reudelhuber T. L., The renin-angiotensin system: peptides and enzymes beyond angiotensin II. Current Opinion in Nephrology and Hypertension 2005 14 2 155 159 2-s2.0-15444367989 (Pubitemid 40396869)
22. Banegas I., Prieto I., Vives F., Alba F., de Gasparo M., Segarra A. B., Hermoso F., Durán R., Ramírez M., Brain aminopeptidases and hypertension. JRAAS 2006 7 3 129 134 2-s2.0-33751010469 10.3317/jraas.2006.021 (Pubitemid 44740946)
23. International Union of Biochemistry, Nomenclature Committee, Enzyme Nomenclature 1984: Recommendations of the Nomenclature Committee for the International Union of Biochemistry on the Nomenclature and Classification of Enzyme-Catalyzed Reactions 1984 Orlando, Fla, USA International Union of Biochemistry Publications Edited by E. C. Webb
24. Mizutani S., Okano K., Hasegawa E., Aminopeptidase A in human placenta. Biochimica et Biophysica Acta 1981 662 1 168 170 2-s2.0-0019819885 (Pubitemid 12216177)
25. Mizutani S., Akiyama H., Kurauchi O., In vitro degradation of angiotensin II (A-II) by human placental subcellular fractions, pregnancy sera and purified placental aminopeptidases. Acta Endocrinologica 1985 110 1 135 139 2-s2.0-0021994713 (Pubitemid 15240699)
26. Yamada R., Mizutani S., Kurauchi O., Okano K., Imaizumi H., Narita O., Tomoda Y., Purification and characterization of human placental aminopeptidase A. Enzyme 1988 40 4 223 230 2-s2.0-0023737918 (Pubitemid 18265980)
27. Wright J. W., Harding J. W., Important roles for angiotensin III and IV in the brain renin-angiotensin system. Brain Research Reviews 1997 25 1 96 124 2-s2.0-0031591786 10.1016/S0165-0173(97)00019-2 (Pubitemid 27459723)
28. Ferrario C. M., Chappell M. C., Novel angiotensin peptides. Cellular and Molecular Life Sciences 2004 61 21 2720 2727 2-s2.0-11144297985 10.1007/s00018-004-4243-4 (Pubitemid 40022433)
29. Clarke N. E., Turner A. J., Angiotensin-converting enzyme 2: the first decade. International Journal of Hypertension 2012 2012 12 307315 10.1155/2012/307315
30. Vauquelin G., Michotte Y., Smolders I., Sarre S., Ebinger G., Dipont A., Vanderbeyden P., Cellular targets for angiotensin II fragments: pharmacological and molecular evidence. JRAAS 2002 3 4 195 204 2-s2.0-0036986979 (Pubitemid 36187374)
31. Mentlein R., Roos T., Proteases involved in the metabolism of angiotensin II, bradykinin, calcitonin gene-related peptide (CGRP), and neuropeptide Y by vascular smooth muscle cells. Peptides 1996 17 4 709 720 2-s2.0-0029948534 10.1016/0196-9781(96)00066-6 (Pubitemid 26238408)
32. De Gasparo M., Catt K. J., Inagami T., Wright J. W., Unger T., International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacological Reviews 2000 52 3 415 472 2-s2.0-0033824138
33. Touyz R. M., Berry C., Recent advances in angiotensin II signaling. Brazilian Journal of Medical and Biological Research 2002 35 9 1001 1015 2-s2.0-0036762815 (Pubitemid 35452880)
34. Glossmann H., Baukal A., Catt K. J., Angiotensin II receptors in bovine adrenal cortex. Modification of angiotensin II binding by guanyl nucleotides. The Journal of Biological Chemistry 1974 249 2 664 666 2-s2.0-0015979835
35. Bennett J. P., Snyder S. H., Angiotensin II binding to mammalian brain membranes. The Journal of Biological Chemistry 1976 251 23 7423 7430 2-s2.0-0017192832
36. Harding J. W., Cook V. I., Miller-Wing A. V., Hanesworth J. M., Sardinia M. F., Hall K. L., Stobb J. W., Swanson G. N., Coleman J. K. M., Wright J. W., Harding E. C., Identification of an AII (38) [AIV] binding site in guinea pig hippocampus. Brain Research 1992 583 1-2 340 343 2-s2.0-0026680189
37. 2 recognition sites in bovine adrenal cortex. European Journal of Pharmacology 1992 219 2 319 322 2-s2.0-0026714768
38. Swanson G. N., Hanesworth J. M., Sardinia M. F., Coleman J. K. M., Wright J. W., Hall K. L., Miller-Wing A. V., Stobb J. W., Cook V. I., Harding E. C., Harding J. W., Discovery of a distinct binding site for angiotensin II (38), a putative angiotensin IV receptor. Regulatory Peptides 1992 40 3 409 419 2-s2.0-0026806962 10.1016/0167-0115(92)90527-2
39. 4 receptor from bovine aortic endothelium with photosensitive analogues of angiotensin IV. Biochemistry 1998 37 12 4280 4287 2-s2.0-0032562243 (Pubitemid 28166451)
40. Wright J. W., Krebs L. T., Stobb J. W., Harding J. W., The angiotensin IV system: functional implications. Frontiers in Neuroendocrinology 1995 16 1 23 52 2-s2.0-0028969970 10.1006/frne.1995.1002
41. 1 receptor subtype in cardiovascular function. Peptides 1996 17 8 1365 1371 2-s2.0-0030445262 10.1016/S0196-9781(96)00226-4 (Pubitemid 27016349)
42. 1 receptor antagonist. Circulation Research 2004 94 11 1451 1457 2-s2.0-2942659879 10.1161/01.RES. 0000130654.56599.40 (Pubitemid 38780317)
43. Yang R., Smolders I., De Bundel D., Fouyn R., Halberg M., Demaegdt H., Vanderheyden P., Dupont A. G., Brain and peripheral angiotensin II type 1 receptors mediate renal vasoconstrictor and blood pressure responses to angiotensin IV in the rat. Journal of Hypertension 2008 26 5 998 1007 2-s2.0-42049085291 10.1097/HJH.0b013e3282f5ed58 (Pubitemid 351520988)
44. 1a-receptor mediated. Journal of Hypertension 2010 28 3 487 494 2-s2.0-77149161422 10.1097/HJH.0b013e3283343250
45. Santiago N. M., Guimarães P. S., Sirvente R. A., Oliveira L. A. M., Irigoyen M. C., Santos R. A. S., Campagnole-Santos M. J., Lifetime overproduction of circulating angiotensin-(17) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling. Hypertension 2010 55 4 889 896 2-s2.0-77950505611 10.1161/HYPERTENSIONAHA.110. 149815
46. Ferreira A. J., Murca T. M., Fraga-Silva R. A., Castro C. H., Raizada M. K., Santos R. A. S., New cardiovascular and pulmonary therapeutic strategies based on the angiotensin-converting enzyme2/angiotensin-(17)/Mas receptor axis. International Journal of Hypertension 2012 2012 13 147825 10.1155/2012/147825
47. Sayeski P. P., Ali M. S., Semeniuk D. J., Doan T. N., Bernstein K. E., Angiotensin II signal transduction pathways. Regulatory Peptides 1998 78 13 19 29 2-s2.0-0032583175 10.1016/S0167-0115(98)00137-2 (Pubitemid 28561513)
48. Dinh D. T., Frauman A. G., Johnston C. I., Fabiani M. E., Angiotensin receptors: distribution, signalling and function. Clinical Science 2001 100 5 481 492 2-s2.0-0037834636 10.1042/CS20000263 (Pubitemid 32434113)
49. Murphy T. J., Alexander R. W., Griendling K. K., Runge M. S., Bernstein K. E., Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991 351 6323 233 236 2-s2.0-0025758883 10.1038/351233a0 (Pubitemid 21896571)
50. Sasaki K., Yamano Y., Bardhan S., Iwai N., Murray J. J., Hasegawa M., Matsuda Y., Inagami T., Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 1991 351 6323 230 233 2-s2.0-0025756064 10.1038/351230a0 (Pubitemid 21896570)
51. Sandberg K., Ji H., Catt K. J., Regulation of angiotensin II receptors in rat brain during dietary sodium changes. Hypertension 1994 23 1, supplement I137 I141 2-s2.0-0027952644 (Pubitemid 24020436)
52. Iwai N., Inagami T., Identification of two subtypes in the rat type I angiotensin II receptor. FEBS Letters 1992 298 2-3 257 260 2-s2.0-0026536743 10.1016/0014-5793(92)80071-N
53. Kakar S. S., Sellers J. C., Devor D. C., Musgrove L. C., Neill J. D., Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. Biochemical and Biophysical Research Communications 1992 183 3 1090 1096 2-s2.0-0026751991 10.1016/S0006-291X(05)80302-X
54. Sasamura H., Hein L., Krieger J. E., Pratt R. E., Kobilka B. K., Dzau V. J., Cloning, characterization, and expression of two angiotensin receptor (AT- 1) isoforms from the mouse genome. Biochemical and Biophysical Research Communications 1992 185 1 253 259 2-s2.0-0026703374 10.1016/S0006-291X(05)80983- 0
55. Konishi H., Kuroda S., Inada Y., Fujisawa Y., Novel subtype of human angiotensin II type 1 receptor: cDNA cloning and expression. Biochemical and Biophysical Research Communications 1994 199 2 467 474 2-s2.0-0028214195 10.1006/bbrc.1994.1252 (Pubitemid 24181685)
56. Guo D. F., Inagami T., The genomic organization of the rat angiotensin II receptor AT(1B). Biochimica et Biophysica Acta 1994 1218 1 91 94 2-s2.0-0028307015 10.1016/0167-4781(94)90105-8
57. Speth R. C., Thompson S. M., Johns S. J., Mukhopadhyay A. K., Raizada M. K., Angiotensin II receptors: structural and functional considerations. Current Concepts: Tissue Renin Angiotensin Systems as Local Regulators in Reproductive and Endocrine Organs 1995 New York, NY, USA Plenum Press 169 192
58. Saavedra J. M., Emerging features of brain angiotensin receptors. Regulatory Peptides 1999 85 1 31 45 2-s2.0-0033619674 10.1016/S0167-0115(99) 00081-6 (Pubitemid 29505283)
59. Thomas W. G., Mendelsohn F. A. O., Angiotensin receptors: form and function and distribution. International Journal of Biochemistry and Cell Biology 2003 35 6 774 779 2-s2.0-0037409311 10.1016/S1357-2725(02)00263-7 (Pubitemid 36379318)
60. 2 receptors do not interact with guanine nucleotide binding proteins. European Journal of Pharmacology 1991 207 2 157 163 2-s2.0-0026427819 10.1016/0922-4106(91)90091-U
61. Kambayashi Y., Bardhan S., Takahashi K., Tsuzuki S., Inui H., Hamakubo T., Inagami T., Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. The Journal of Biological Chemistry 1993 268 33 24543 24546 2-s2.0-0027443482 (Pubitemid 23335457)
62. Mukoyama M., Nakajima M., Horiuchi M., Sasamura H., Pratt R. E., Dzau V. J., Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. The Journal of Biological Chemistry 1993 268 33 24539 24542 2-s2.0-0027362063 (Pubitemid 23335456)
63. Young D., Waitches G., Birchmeier C., Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell 1986 45 5 711 719 2-s2.0-0022536710 (Pubitemid 16063134)
64. Xu X., Quiambao A. B., Roveri L., Pardue M. T., Marx J. L., Röhlich P., Peachey N. S., Al-Ubaidi M. R., Degeneration of cone photoreceptors induced by expression of the Mas1 protooncogene. Experimental Neurology 2000 163 1 207 219 2-s2.0-0034111311 10.1006/exnr.2000.7370 (Pubitemid 30314376)
65. Alenina N., Xu P., Rentzsch B., Patkin E. L., Bader M., Genetically altered animal models for Mas and angiotensin-(17). Experimental Physiology 2008 93 5 528 537 2-s2.0-42649141954 10.1113/expphysiol.2007.040345 (Pubitemid 351595044)
66. Young D., O'Neill K., Jessell T., Wigler M., Characterization of the rat mas oncogene and its high-level expression in the hippocampus and cerebral cortex of rat brain. Proceedings of the National Academy of Sciences of the United States of America 1988 85 14 5339 5342 2-s2.0-0023746492
67. Bader M., Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues. FEBS Letters 1995 357 1 27 32 2-s2.0-0028894102 10.1016/0014-5793(94)01292-9
68. Pinheiro S. V. B., Simões E Silva A. C., Sampaio W. O., De Paula R. D., Mendes E. P., Bontempo E. D., Pesquero J. B., Walther T., Alenina N., Bader M., Bleich M., Santos R. A. S., Nonpeptide AVE 0991 is an angiotensin-(17) receptor mas agonist in the mouse kidney. Hypertension 2004 44 4 490 496 2-s2.0-4644372221 10.1161/01.HYP.0000141438.64887.42 (Pubitemid 39281501)
69. Ferreira A. J., Murca T. M., Fraga-Silva R. A., Castro C. H., Raizada M. K., Santos R. A. S., New cardiovascular and pulmonary therapeutic strategies based on the angiotensin-converting enzyme2/angiotensin-(17)/Mas receptor axis. International Journal of Hypertension 2012 2012 13 147825 10.1155/2012/147825
70. Xu P., Sriramula S., Lazartigues E., ACE2/ANG-(17)/Mas pathway in the brain: the axis of good. American Journal of Physiology 2011 300 4 R804 R817 2-s2.0-79954555219 10.1152/ajpregu.00222.2010
71. Grobe J. L., Mecca A. P., Lingis M., Shenoy V., Bolton T. A., Machado J. M., Speth R. C., Raizada M. K., Katovich M. J., Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(17). American Journal of Physiology 2007 292 2 H736 H742 2-s2.0-33846987938 10.1152/ajpheart.00937.2006
72. Ferreira A. J., Castro C. H., Guatimosim S., Almeida P. W. M., Gomes E. R. M., Dias-Peixoto M. F., Alves M. N. M., Fagundes-Moura C. R., Rentzsch B., Gava E., Almeida A. P., Guimarées A. M., Kitten G. T., Reudelhuber T., Bader M., Santos R. A. S., Attenuation of isoproterenol-induced cardiac fibrosis in transgenic rats harboring an angiotensin-(17)-producing fusion protein in the heart. Therapeutic Advances in Cardiovascular Disease 2010 4 2 83 96 2-s2.0-77950497363 10.1177/1753944709353426
73. Santiago N. M., Guimarães P. S., Sirvente R. A., Oliveira L. A. M., Irigoyen M. C., Santos R. A. S., Campagnole-Santos M. J., Lifetime overproduction of circulating angiotensin-(17) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling. Hypertension 2010 55 4 889 896 2-s2.0-77950505611 10.1161/HYPERTENSIONAHA.110. 149815
74. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M., Nichols A., Tummino P., Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. The Journal of Biological Chemistry 2002 277 17 14838 14843 2-s2.0-18544378161 10.1074/jbc.M200581200 (Pubitemid 34952556)
75. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R., Breitbart R. E., Acton S., A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 19. Circulation Research 2000 87 5 E1 E9 2-s2.0-0038053724
76. Hernández Prada J. A., Ferreira A. J., Katovich M. J., Shenoy V., Qi Y., Santos R. A. S., Castellano R. K., Lampkins A. J., Gubala V., Ostrov D. A., Raizada M. K., Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008 51 5 1312 1317 2-s2.0-42349105833 10.1161/HYPERTENSIONAHA.107. 108944 (Pubitemid 351555943)
77. Savergnini S. Q., Beiman M., Lautner R. Q., De Paula-Carvalho V., Allahdadi K., Pessoa D. C., Costa-Fraga F. P., Fraga-Silva R. A., Cojocaru G., Cohen Y., Bader M., De Almeida A. P., Rotman G., Santos R. A. S., Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the mas receptor. Hypertension 2010 56 1 112 120 2-s2.0-77953811506 10.1161/HYPERTENSIONAHA.110.152942
78. Barret A. J., Rawlings N. D., Woessner J. F., Handbook of Proteolytic Enzymes 1998 London, UK Academic Press
79. Albiston A. L., McDowall S. G., Matsacos D., Sim P., Clune E., Mustafa T., Lee J., Mendelsohn F. A. O., Simpson R. J., Connolly L. M., Chai S. Y., Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin regulated aminopeptidase. The Journal of Biological Chemistry 2001 276 52 48623 48626 2-s2.0-0035966085 10.1074/jbc.C100512200
80. Phillips M. I., Functions of angiotensin in the central nervous system. Annual Review of Physiology 1987 49 413 435 2-s2.0-0023161147 (Pubitemid 17053904)
81. Wright J. W., Harding J. W., Regulatory role of brain angiotensins in the control of physiological and behavioral responses. Brain Research Reviews 1992 17 3 227 262 2-s2.0-0026471753 10.1016/0165-0173(92)90018-H
82. Felix D., Schlegel W., Angiotensin receptive neurones in the subfornical organ. Structure-activity relations. Brain Research 1978 149 1 107 116 2-s2.0-0018099439 10.1016/0006-8993(78)905917 (Pubitemid 8350027)
83. Harding J. W., Felix D., Angiotensin-sensitive neurons in the rat paraventricular nucleus: relative potencies of angiotensin II and angiotensin III. Brain Research 1987 410 1 130 134 2-s2.0-0023251129 (Pubitemid 17075194)
84. Harding J. W., Felix D., The effects of the aminopeptidase inhibitors amastatin and bestatin on angiotensin-evoked neuronal activity in rat brain. Brain Research 1987 424 2 299 304 2-s2.0-0023589150 (Pubitemid 18047674)
85. Harding J. W., Jensen L. L., Hanesworth J. M., Roberts K. A., Page T. A., Wright J. W., Release of angiotensins in paraventricular nucleus of rat in response to physiological and chemical stimuli. American Journal of Physiology 1992 262 1 F17 F23 2-s2.0-0026579831
86. Jensen L. L., Harding J. W., Wright J. W., Increased blood pressure induced by central application of aminopeptidase inhibitors is angiotensinergic-dependent in normotensive and hypertensive rat strains. Brain Research 1989 490 1 48 55 2-s2.0-0024392915 (Pubitemid 19154960)
87. 125I-angiotensins in the spontaneously hypertensive rat. Journal of Neurochemistry 1987 49 2 651 654 2-s2.0-0023189107 (Pubitemid 17101203)
88. Wright J. W., Jensen L. L., Cushing L. L., Harding J. W., Leucine aminopeptidase M-induced reductions in blood pressure in spontaneously hypertensive rats. Hypertension 1989 13 6 910 915 2-s2.0-0024352497 (Pubitemid 19157989)
89. Wright J. W., Mizutani S., Murray C. E., Amir H. Z., Harding J. W., Aminopeptidase-induced elevations and reductions in blood pressure in the spontaneously hypertensive rat. Journal of Hypertension 1990 8 10 969 974 2-s2.0-0024993749 (Pubitemid 20368621)
90. D-Asp1]angiotensin II, as a pressor agent in rats. Brain Research 1990 514 1 5 10 2-s2.0-0025215551 10.1016/0006-8993(90) 90428-E (Pubitemid 20147580)
91. Wright J. W., Tamura-Myers E., Wilson W. L., Roques B. P., Llorens-Cortes C., Speth R. C., Harding J. W., Conversion of brain angiotensin II to angiotensin III is critical for pressor response in rats. American Journal of Physiology 2003 284 3 R725 R733 2-s2.0-0037343289 (Pubitemid 36342805)
92. Stanton A., Potential of renin inhibition in cardiovascular disease. JRAAS 2003 4 1 6 10 2-s2.0-0037364810 (Pubitemid 36443380)
93. Zisman L. S., Abraham W. T., Meixell G. E., Vamvakias B. N., Quaife R. A., Lowes B. D., Roden R. L., Peacock S. J., Groves B. M., Raynolds M. V., Bristow M. R., Perryman M. B., Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway. The Journal of Clinical Investigation 1995 96 3 1490 1498 2-s2.0-0029166084
94. Dell'Italia I. J., Sabri A., Mann D. L., Activation of the renin-angiotensin system in hypertrophy and heart failure. Heart Failure 2004 Philadelphia, Pa, USA Saunders
95. Liu Y. H., Yang X. P., Sharov V. G., Nass O., Sabbah H. N., Peterson E., Carretero O. A., Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. The Journal of Clinical Investigation 1997 99 8 1926 1935 2-s2.0-0031003230 (Pubitemid 27175940)
96. Adams K. F. Jr., Pathophysiologic role of the renin-angiotensin- aldosterone and sympathetic nervous systems in heart failure. American Journal of Health-System Pharmacy 2004 61 supplement 2 S4 S13 2-s2.0-3442884555 (Pubitemid 39482913)
97. Brilla C. G., Pick R., Tan L. B., Janicki J. S., Weber K. T., Remodeling of the rat right and left ventricles in experimental hypertension. Circulation Research 1990 67 6 1355 1364 2-s2.0-0025675680
98. Sabbah H. N., Stein P. D., Kono T., Gheorghiade M., Levine T. B., Jafri S., Hawkins E. T., Goldstein S., A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. American Journal of Physiology 1991 260 4 H1379 H1384 2-s2.0-0025865760
99. McKelvie R. S., Yusuf S., Pericak D., Avezum A., Burns R. J., Probstfield J., Tsuyuki R. T., White M., Rouleau J., Latini R., Maggioni A., Young J., Pogue J., Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: the RESOLVD pilot study investigators. Circulation 1999 100 10 1056 1064 2-s2.0-0033533456 (Pubitemid 29416231)
100. Pitt B., Reichek N., Willenbrock R., Zannad F., Phillips R. A., Roniker B., Kleiman J., Krause S., Burns D., Williams G. H., Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-Left Ventricular Hypertrophy Study. Circulation 2003 108 15 1831 1838 2-s2.0-0142085752 10.1161/01.CIR.0000091405. 00772.6E (Pubitemid 37296092)
101. Hayashida W., Donckier J., Van Mechelen H., Charlier A. A., Pouleur H., Diastolic properties in canine hypertensive left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition and angiotensin II type-1 receptor blockade. Cardiovascular Research 1997 33 1 54 62 2-s2.0-0031032106 10.1016/S0008-6363(96)00194-0 (Pubitemid 27019099)
102. Wachtell K., Bella J. N., Rokkedal J., Palmieri V., Papademetriou V., Dahlöf B., Aalto T., Gerdts E., Devereux R. B., Change in diastolic left ventricular filling after one year of antihypertensive treatment: the losartan intervention for endpoint reduction in hypertension (LIFE) study. Circulation 2002 105 9 1071 1076 2-s2.0-0037022929 10.1161/hc0902.104599 (Pubitemid 34212616)
103. Díez J., Querejeta R., López B., González A., Larman M., Martínez Ubago J. L., Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002 105 21 2512 2517 2-s2.0-0037188574 10.1161/01.CIR.0000017264.66561.3D (Pubitemid 34568973)
104. Yusuf S., Pfeffer M. A., Swedberg K., Granger C. B., Held P., McMurray J. J. V., Michelson E. L., Olofsson B., Östergren J., Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. The Lancet 2003 362 9386 777 781 2-s2.0-0041408234 10.1016/S0140-6736(03)14285-7 (Pubitemid 37093918)
105. Reaux A., Fournie-Zaluski M. C., David C., Zini S., Roques B. P., Corvol P., Llorens-Cortes C., Aminopeptidase A inhibitors as potential central antihypertensive agents. Proceedings of the National Academy of Sciences of the United States of America 1999 96 23 13415 13420 2-s2.0-0033539511 10.1073/pnas.96.23.13415
106. Morton J. J., Casals-Stenzel J., Lever A. F., Inhibitors of the renin-angiotensin system in experimental hypertension, with a note on the measurement of angiotensin I, II and III during infusion of converting-enzyme inhibitor. British Journal of Clinical Pharmacology 1979 7 supplement 2 233S 241S 2-s2.0-0018357310 (Pubitemid 9220529)
107. Fournie-Zaluski M. C., Fassot C., Valentin B., Djordjijevic D., Reaux-Le Goazigo A., Corvol P., Roques B. P., Llorens-Cortes C., Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension. Proceedings of the National Academy of Sciences of the United States of America 2004 101 20 7775 7780 2-s2.0-2542459372 10.1073/pnas.0402312101 (Pubitemid 38678554)
108. Zini S., Fournie-Zaluski M. C., Chauvel E., Roques B. P., Corvol P., Llorens-Cortes C., Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proceedings of the National Academy of Sciences of the United States of America 1996 93 21 11968 11973 2-s2.0-0029859206 10.1073/pnas.93.21.11968 (Pubitemid 26347232)
109. Ferrario C. M., Angiotensin-converting enzyme 2 and angiotensin-(17): an evolving story in cardiovascular regulation. Hypertension 2006 47 3 515 521 2-s2.0-33644970894 10.1161/01.HYP.0000196268.08909.fb (Pubitemid 43843868)
110. Kokje R. J., Wilson W. L., Brown T. E., Karamyan V. T., Wright J. W., Speth R. C., Central pressor actions of aminopeptidase-resistant angiotensin II analogs: challenging the angiotensin III hypothesis. Hypertension 2007 49 6 1328 1335 2-s2.0-34249336753 10.1161/HYPERTENSIONAHA.107.087130 (Pubitemid 46809376)
111. Reaux A., Fournie-Zaluski M. C., Llorens-Cortes C., Angiotensin III: a central regulator of vasopressin release and blood pressure. Trends in Endocrinology and Metabolism 2001 12 4 157 162 2-s2.0-0035347330 (Pubitemid 33713556)
112. Zini S., Demassey Y., Fournié-Zaluski M. C., Bischoff L., Corvol P., Llorens-Cortès C., Sanderson P., Inhibition of vasopressinergic neurons by central injection of a specific aminopeptidase A inhibitor. NeuroReport 1998 9 5 825 828 2-s2.0-0032579918 (Pubitemid 28179283)
113. Réaux A., De Mota N., Zini S., Cadel S., Fournié-Zaluski M. C., Roques B. P., Corvol P., Llorens-Cortès C., PC18, a specific aminopeptidase N inhibitor, induces vasopressin release by increasing the half-life of brain Angiotensin III. Neuroendocrinology 1999 69 5 370 376 2-s2.0-0345711597 10.1159/000054439 (Pubitemid 29240410)
114. Bodineau L., Frugière A., Marc Y., Inguimbert N., Fassot C., Balavoine F., Roques B., Llorens-Cortes C., Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension 2008 51 5 1318 1325 2-s2.0-39649093737 10.1161/HYPERTENSIONAHA.107. 098772 (Pubitemid 351555944)
115. Bodineau L., Frugière A., Marc Y., Claperon C., Llorens-Cortes C., Aminopeptidase A inhibitors as centrally acting antihypertensive agents. Heart Failure Reviews 2008 13 3 311 319 2-s2.0-42049107269 10.1007/s10741-007-9077-3
116. Song L., Wilk S., Healy D. P., Aminopeptidase A antiserum inhibits intracerebroventricular angiotensin II-induced dipsogenic and pressor responses. Brain Research 1997 744 1 1 6 2-s2.0-0031012909 10.1016/S0006-8993(96)00952-3 (Pubitemid 27035000)
117. Marc Y., Llorens-Cortes C., The role of the brain renin-angiotensin system in hypertension: implications for new treatment. Progress in Neurobiology 2011 95 2 89 103 10.1016/j.pneurobio.2011.06.006
118. Ahmad S., Ward P. E., Role of aminopeptidase activity in the regulation of the pressor activity of circulating angiotensins. Journal of Pharmacology and Experimental Therapeutics 1990 252 2 643 650 2-s2.0-0025321792 (Pubitemid 20101879)
119. 125I-angiotensins in rat. Journal of Neurochemistry 1986 46 4 1292 1297 2-s2.0-0022516143 (Pubitemid 16010985)
120. Rich D. H., Moon B. J., Harbeson S., Inhibition of aminopeptidases by amastatin and bestatin derivatives. Effect of inhibitor structure on slow-binding processes. Journal of Medicinal Chemistry 1984 27 4 417 422 2-s2.0-0021277915 (Pubitemid 14133727)
121. 2+-activated aspartate aminopeptidase activity, subcellular localization in young and adult rat brain. Brain Research 1990 522 1 165 167 2-s2.0-0025195260 10.1016/0006-8993(90)91595-8 (Pubitemid 20208803)
122. Ardaillou R., Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects. Current Opinion in Nephrology and Hypertension 1997 6 1 28 34 2-s2.0-0031045996 10.1097/00041552-199701000-00006 (Pubitemid 27110154)
123. Ramírez M., Prieto I., Alba F., Vives F., Banegas I., de Gasparo M., Role of central and peripheral aminopeptidase activities in the control of blood pressure: a working hypothesis. Heart Failure Reviews 2008 13 3 339 353 2-s2.0-42049113850 10.1007/s10741-007-9066-6
124. Bernardi S., Burns W. C., Toffoli B., Angiotensin converting enzyme 2 regulates renal atrial natriuretic peptide through angiotensin-(17). Clinical Science 2012 123 1 29 37
125. Wright J. W., Harding J. W., Brain renin-angiotensin-A new look at an old system. Progress in Neurobiology 2011 95 1 49 67 2-s2.0-79960675107 10.1016/j.pneurobio.2011.07.001
126. Goto Y., Hattori A., Ishii Y., Tsujimoto M., Reduced activity of the hypertension-associated Lys528Arg mutant of human adipocyte-derived leucine aminopeptidase (A-LAP)/ER-aminopeptidase-1. FEBS Letters 2006 580 7 1833 1838 2-s2.0-33644908217 10.1016/j.febslet.2006.02.041
127. Ishii M., Hattori A., Numaguchi Y., Tsujimoto M., Ishiura S., Kobayashi H., Murohara T., Wright J. W., Mizutani S., The effect of recombinant aminopeptidase A on hypertension in spontaneously hypertensive rats: its effect in comparison with candesartan. Hormone and Metabolic Research 2008 40 12 887 891 2-s2.0-58149123438 10.1055/s-0028-1083783
128. Healy D. P., Song L., Kidney aminopeptidase A and hypertension, part I: spontaneously hypertensive rats. Hypertension 1999 33 2 740 745 2-s2.0-0033031551 (Pubitemid 29091658)
129. 1-receptors and ACE synergistically potentiates antihypertensive effects in SHR. Journal of Hypertension 2004 22 3 611 618 2-s2.0-5044250452 10.1097/00004872-200403000-00025 (Pubitemid 38368496)
130. Mizutani S., Okano K., Hasegawa E., Human placental leucine aminopeptidase (P-LAP) as a hypotensive agent. Experientia 1982 38 7 821 822 2-s2.0-0020332456 (Pubitemid 12013667)
131. Mizutani S., Furuhashi M., Imaizumi H., Ito Y., Kurauchi O., Tomoda Y., Effects of human placental aminopeptidases in spontaneously hypertensive rats. Medicinal Science Research 1987 15 1 1203 1204
132. Wright J. W., Sullivan M. J., Harding J. W., Dysfunction of central angiotensinergic aminopeptidase activity in spontaneously hypertensive rats. Neuroscience Letters 1985 61 3 351 356 2-s2.0-0022366286 (Pubitemid 16198797)
133. Nakashima Y., Ohno Y., Itakura A., Takeuchi M., Murata Y., Kuno N., Mizutani S., Possible involvement of aminopeptidase A in hypertension in spontaneously hypertensive rats (SHRs) and change of refractoriness in response to angiotensin II in pregnant SHRs. Journal of Hypertension 2002 20 11 2233 2238 2-s2.0-0036853679 10.1097/00004872-200211000-00023 (Pubitemid 35388242)
134. Mizutani S., Wright J., Kobayashi H., A new approach regarding the treatment of preeclampsia and preterm labor. Life Sciences 2011 88 1-2 17 23 2-s2.0-78650519682 10.1016/j.lfs.2010.10.013
135. Kobayashi H., Mizutani S., Wright J. W., Placental leucine aminopeptidase- and aminopeptidase A-deficient mice offer insight concerning the mechanisms underlying preterm labor and preeclampsia. Journal of Biomedicine and Biotechnology 2011 2011 12 2-s2.0-79251556537 10.1155/2011/286947 286947
136. Danziger R. S., Aminopeptidase N in arterial hypertension. Heart Failure Reviews 2008 13 3 293 298 2-s2.0-42049114529 10.1007/s10741-007-9061-y
137. Lerche C., Vogel L. K., Shapiro L. H., Norén O., Sjöström H., Human aminopeptidase N is encoded by 20 exons. Mammalian Genome 1996 7 9 712 713 2-s2.0-0030240121 (Pubitemid 126443522)
138. Yamamoto N., Nakayama J., Yamakawa-Kobayashi K., Hamaguchi H., Miyazaki R., Arinami T., Identification of 33 polymorphisms in the adipocyte-derived leucine aminopeptidase (ALAP) gene and possible association with hypertension. Human Mutation 2002 19 3 251 257 2-s2.0-0036192091 10.1002/humu.10047 (Pubitemid 34195186)
139. Williams J. S., Raji A., Williams G. H., Conlin P. R., Nonmodulating hypertension is associated with insulin resistance and the Lys528Arg variant human adipocyte-derived leucine aminopeptidase. Hypertension 2006 48 4, article e33
140. Sri Krishna K., Kirubakaran M. G., Pandey A. P., Kanagasabapathy A. S., Urinary N-acetyl- β -d-glucosaminidase and aminopeptidase N in the diagnosis of graft rejection after live donor renal transplantation. Clinica Chimica Acta 1985 150 2 69 85 2-s2.0-0022367110 (Pubitemid 16239441)
141. Kitamura Y., Watanabe M., Komatsubara S., Sakata Y., Urinary excretion of glycine.prolile dipeptidile aminopeptidase, N-acetyl-beta-D-glucosaminidase, alanine aminopeptidase and low molecular protein in patients with renal cell carcinoma. Acta Urologica Japonica 1990 36 5 535 539 2-s2.0-0025423930
142. Padia S. H., Howell N. L., Kemp B. A., Fournie-Zaluski M. C., Roques B. P., Carey R. M., Intrarenal aminopeptidase N inhibition restores defective angiontesin II type 2-mediated natriuresis in spontaneously hypertensive rats. Hypertension 2010 55 2 474 480 2-s2.0-74949094651 10.1161/HYPERTENSIONAHA.109. 144956
143. Padia S. H., Kemp B. A., Howell N. L., Gildea J. J., Keller S. R., Carey R. M., Intrarenal angiotensin III infusion induces natriuresis and angiotensin type 2 receptor translocation in Wistar-Kyoto but not in spontaneously hypertensive rats. Hypertension 2009 53 2 338 343 2-s2.0-59849116222 10.1161/HYPERTENSIONAHA.108.124198
144. Bauvois B., Dauzonne D., Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Medicinal Research Reviews 2006 26 1 88 130 2-s2.0-33644875741 10.1002/med.20044 (Pubitemid 43986471)
145. Düsing R., Optimizing blood pressure control through the use of fixed combinations. Vascular Health and Risk Management 2010 6 321 325 2-s2.0-77955901459
146. Kearney P. M., Whelton M., Reynolds K., Muntner P., Whelton P. K., He J., Global burden of hypertension: analysis of worldwide data. The Lancet 2005 365 9455 217 223 2-s2.0-12344282783 10.1016/S0140-6736(05)17741-1 (Pubitemid 40138015)
147. Wolf-Maier K., Cooper R. S., Kramer H., Banegas J. R., Giampaoli S., Joffres M. R., Poulter N., Primatesta P., Stegmayr B., Thamm M., Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004 43 1 10 17 2-s2.0-9144248446 10.1161/01.HYP.0000103630.72812. 10 (Pubitemid 38031904)